Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Neoplasm Metastasis 2Glioma 2Glioblastoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Nasopharyngeal Carcinoma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinosarcoma 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × LY-2157299 × Clear all
NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Providence Health & Services

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡